Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:27:50 2026-03-11 pm EDT			5-day change	1st Jan Change
116.00 ^USD	-0.94%		-3.51%	+10.26%

Mar. 10	Merck's Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says	MT
Mar. 10	BioNTech founders plan exit to set up new venture, shares slump	RE

Press Releases

Mar. 03	Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion	PR
Mar. 02	Merck - KEYTRUDA Plus Paclitaxel with or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival versus Paclitaxel with or without Bevacizumab in Patients	AQ
Mar. 02	Merck - WELIREG plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients with Advanced Renal Cell Carcinoma	AQ
Mar. 02	Merck - KEYTRUDA plus Padcev Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery	AQ
Mar. 02	Merck - KEYTRUDA plus WELIREG Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients with Earlier-Stage Renal Cell Carcinoma	AQ
Feb. 28	KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)	BU
Feb. 28	WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)	BU
Feb. 27	KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer	BU
Feb. 27	KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery	BU
Feb. 25	FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis	BU
Feb. 25	Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026	BU
Feb. 24	Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge	PR
Feb. 24	Merck to Participate in the TD Cowen 46th Annual Health Care Conference	BU
Feb. 24	Nykode Therapeutics Announces New Interim Data from the VB-C-03 Trial Showing Encouraging Anti-Tumor Activity and Tolerability of Abi-suva (VB10.16)	AQ
Feb. 23	Merck Evolves Human Health Operating Structure to Support Portfolio Execution	BU
Feb. 19	Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons	BU
Feb. 18	Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine	BU
Feb. 17	Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications	AQ
Feb. 12	Merck - KEYTRUDA and KEYTRUDA QLEX, Plus Paclitaxel +/- Bevacizumab, Approved for Certain Adults with PD-L1+ Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment	AQ
Feb. 12	Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	AQ
Feb. 12	Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium	BU
Feb. 11	KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment	BU
Feb. 05	Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants	AQ
Feb. 03	Merck : remembers Dr. William Foege, Architect of Early Mectizan® Delivery Efforts - Merck.com	PU
Feb. 03	Merck : Icon 4Q25 Merck Earnings Presentation	PU